A retrospective study comparing risk of anterior uveitis during treatment with secukinumab versus tumour necrosis factor inhibitors
Latest Information Update: 25 Jun 2021
At a glance
- Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary) ; Secukinumab (Primary)
- Indications Ankylosing spondylitis
- Focus Adverse reactions
- 25 Jun 2021 New trial record
- 15 Jun 2021 Results published in the Annals of the Rheumatic Diseases